Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

Status Completed

Clinical Trial Summary

The purpose of the study was to evaluate the immunogenicity and describe the safety of Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine compared to the licensed Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 (MENVEO®) vaccine in children 2 to 9 years of age in the United States (US) and Puerto Rico. Primary objective: - To demonstrate the non-inferiority of the vaccine seroresponse to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW Conjugate vaccine compared to that observed following the administration of a single dose of MENVEO® in children aged 2 to 9 years. Secondary objectives: - To compare the serum bactericidal assay using human complement (hSBA) antibody geometric mean titers (GMTs) of meningococcal serogroups A, C, Y, and W following the administration of MenACYW Conjugate vaccine to those observed following the administration of MENVEO® in children 2 to 9 years of age. - To evaluate the hSBA antibody GMTs of meningococcal serogroups A, C, Y, and W following the administration of MenACYW Conjugate vaccine and those observed following the administration of MENVEO® in children 2 to 5 years of age, and in children 6 to 9 years of age, respectively. - To evaluate the hSBA vaccine seroresponse to meningococcal serogroups A, C, Y, and W before and 30 days (+14 days) post-vaccination in children 2 to 5 years of age, and in children 6 to 9 years of age, respectively. Observational objective: - To describe the safety profile of MenACYW Conjugate vaccine and that of the licensed MENVEO®.

Clinical Trial Description

Healthy children were randomized and received a single dose of either MenACYW Conjugate vaccine or MENVEO®. They were assessed for immunogenicity at baseline (pre-vaccination) and at 30-44 days post-vaccination. Safety information were collected post-vaccination and throughout the entire study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03077438
Study type	Interventional
Source	Sanofi
Contact
Status	Completed
Phase	Phase 3
Start date	February 17, 2017
Completion date	October 10, 2017

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT03445416` - Increasing Healthcare Engagement Via Routine Vaccination Among Young Black Men Who Have Sex With Men	N/A
Completed	`NCT02526394` - Pertussis and Meningitis C Concomitant Vaccination in Adolescents	Phase 4
Completed	`NCT01442675` - Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine	Phase 2
Completed	`NCT00539032` - Immunology and Safety of Menactra® in Children in Saudi Arabia	Phase 3
Terminated	`NCT00428051` - Colombia Epidemiologic Surveillance Study	N/A
Recruiting	`NCT05496673` - Meningitis: Burden, Causes, Screening and Prevention in Rural Northern Uganda	N/A
Completed	`NCT02003495` - Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine	Phase 3
Recruiting	`NCT00901602` - Lebanese Interhospital Pneumococcal Surveillance Program
Completed	`NCT00850603` - Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune®	Phase 4
Completed	`NCT02591290` - Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects	Phase 4
Completed	`NCT03112031` - Treatment With Tamoxifen in Cryptococcal Meningitis	Phase 2
Completed	`NCT02881957` - Hypovitaminosis D in Neurocritical Patients	Phase 2/Phase 3
Completed	`NCT06334796` - Artificial Intelligence-powered Virtual Assistant for Emergency Triage in Neurology	Early Phase 1
Completed	`NCT03378258` - Petechiae In Children (PIC) Study: Defining A Clinical Decision Rule for The Management Of Fever and Non-Blanching Rashes In Children Including The Role Of Point Of Care Testing For Procalcitonin & Neisseria Meningitidis DNA.
Recruiting	`NCT05637645` - Different Approaches of Spinal Anesthesia in Patients Undergoing Cesarean Section	N/A
Completed	`NCT02841254` - Diagnostic Performance of Clinical Signs Patients Suspected of Meningitis to Emergencies	N/A
Completed	`NCT02003313` - Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine	Phase 3
Recruiting	`NCT01619462` - Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children	Phase 3
Completed	`NCT01239043` - Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination	Phase 2
Completed	`NCT00495690` - Impact of Daily Zinc Supplementation to Infants Born With Low Birth Weight on Death and Severe Disease	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms